Pulmonary hypertension in bronchopulmonary dysplasia

Seminars in Perinatology

Volumn 37, Issue 2, 2013, Pages 124-131

  Berkelhamer, Sara K ^a   Mestan, Karen K ^a   Steinhorn, Robin H ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic lung disease; Fetal growth restriction; Prematurity; Pulmonary vascular disease; Pulmonary vasodilators

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ILOPROST; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; TREPROSTINIL; TROPONIN T; URIC ACID; VASODILATOR AGENT;

ADD ON THERAPY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; ECHOCARDIOGRAPH; ELECTROCARDIOGRAPHY; EXTREMELY LOW BIRTH WEIGHT; HEART CATHETERIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; JAW PAIN; LUNG DYSPLASIA; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR PATHOLOGY; MULTIPOTENT STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; SCREENING TEST; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC DISEASE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT PLANNING; VASODILATATION;

BRONCHOPULMONARY DYSPLASIA; ECHOCARDIOGRAPHY; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; INFANT, PREMATURE; VASODILATOR AGENTS;

EID: 84876122586     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2013.01.009     Document Type: Review

References (78)

1. Doyle L.W., Anderson P.J. Long-term outcomes of bronchopulmonary dysplasia. Semin Fetal Neonatal Med 2009, 14(6):391-395.
2. Anderson P.J., Doyle L.W. Neurodevelopmental outcome of bronchopulmonary dysplasia. Semin Perinatol 2006, 30(4):227-232.
3. Short E.J., Kirchner H.L., Asaad G.R., et al. Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: analysis using a severity-based classification system. Arch Pediatr Adolesc Med 2007, 161(11):1082-1087.
4. Gough A., Spence D., Linden M., Halliday H.L., McGarvey L.P. General and respiratory health outcomes in adult survivors of bronchopulmonary dysplasia: a systematic review. Chest 2012, 141(6):1554-1567.
5. Abman S.H., Ivy D.D. Recent progress in understanding pediatric pulmonary hypertension. Curr Opin Pediatr 2011, 23(3):298-304.
6. Slaughter J.L., Pakrashi T., Jones D.E., South A.P., Shah T.A. Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation. J Perinatol 2011, 31(10):635-640.
7. An H.S., Bae E.J., Kim G.B., et al. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Korean Circ J 2010, 40(3):131-136.
8. Kim D.H., Kim H.S., Choi C.W., Kim E.K., Kim B.I., Choi J.H. Risk factors for pulmonary artery hypertension in preterm infants with moderate or severe bronchopulmonary dysplasia. Neonatology 2012, 101(1):40-46.
9. Khemani E., McElhinney D.B., Rhein L., et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007, 120(6):1260-1269.
10. Bhat R., Salas A.A., Foster C., Carlo W.A., Ambalavanan N. Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics 2012, 129(3):e682-e689.
11. Collaco J.M., Romer L.H., Stuart B.D., et al. Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia. Pediatr Pulmonol 2012, 47(11):1042-1053.
12. Farquhar M., Fitzgerald D.A. Pulmonary hypertension in chronic neonatal lung disease. Paediatr Respir Rev 2010, 11(3):149-153.
13. Jobe A.H. The new bronchopulmonary dysplasia. Curr Opin Pediatr 2011, 23(2):167-172.
14. Abman S.H., Wolfe R.R., Accurso F.J., Koops B.L., Bowman C.M., Wiggins J.W. Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia. Pediatrics 1985, 75(1):80-84.
15. Mourani P.M., Ivy D.D., Gao D., Abman S.H. Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2004, 170(9):1006-1013.
16. Jakkula M., Le Cras T.D., Gebb S., et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000, 279(3):L600-L607.
17. Le Cras T.D., Markham N.E., Tuder R.M., Voelkel N.F., Abman S.H. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 2002, 283(3):L555-L562.
18. Mourani P.M., Mullen M., Abman S.H. Pulmonary hypertension in bronchopulmonary dysplasia. Progr Pediatr Cardiol 2009, 27:43-48.
19. Hislop A.A., Haworth S.G. Pulmonary vascular damage and the development of cor pulmonale following hyaline membrane disease. Pediatr Pulmonol 1990, 9(3):152-161.
20. Check J, Gotteiner N, Liu X, et al. Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia. J Perinatol advance online publication, January 17, 2013; doi:10.1038/jp.2012.164,PMID: 23328924.
21. Rozance P.J., Seedorf G.J., Brown A., et al. Intrauterine growth restriction decreases pulmonary alveolar and vessel growth and causes pulmonary artery endothelial cell dysfunction in vitro in fetal sheep. Am J Physiol Lung Cell Mol Physiol 2011, 301(6):L860-L871.
22. MacRitchie A.N., Albertine K.H., Sun J., et al. Reduced endothelial nitric oxide synthase in lungs of chronically ventilated preterm lambs. Am J Physiol Lung Cell Mol Physiol 2001, 281(4):L1011-L1020.
23. Afshar S., Gibson L.L., Yuhanna I.S., et al. Pulmonary NO synthase expression is attenuated in a fetal baboon model of chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2003, 284(5):L749-L758.
24. Bland R.D., Ling C.Y., Albertine K.H., et al. Pulmonary vascular dysfunction in preterm lambs with chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2003, 285(1):L76-L85.
25. Farrow K.N., Groh B.S., Schumacker P.T., et al. Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ Res 2008, 102(2):226-233.
26. Farrow K.N., Lee K.J., Perez M., et al. Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase 5 activity in fetal pulmonary artery smooth muscle cells. Antioxid Redox Signal 2012, 17(3):460-470.
27. Farrow KN, Steinhorn RH. Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension. Handb Exp Pharmacol. 2011(204):251-277.
28. Puchalski M.D., Lozier J.S., Bradley D.J., Minich L.L., Tani L.Y. Electrocardiography in the diagnosis of right ventricular hypertrophy in children. Pediatrics 2006, 118(3):1052-1055.
29. Arcasoy S.M., Christie J.D., Ferrari V.A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003, 167(5):735-740.
30. Mourani P.M., Sontag M.K., Younoszai A., Ivy D.D., Abman S.H. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008, 121(2):317-325.
31. Drossner D.M., Kim D.W., Maher K.O., Mahle W.T. Pulmonary vein stenosis: prematurity and associated conditions. Pediatrics 2008, 122(3):e656-e661.
32. Taylor C.J., Derrick G., McEwan A., Haworth S.G., Sury M.R. Risk of cardiac catheterization under anaesthesia in children with pulmonary hypertension. Br J Anaesth 2007, 98(5):657-661.
33. Hill K.D., Lim D.S., Everett A.D., Ivy D.D., Moore J.D. Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the magic registry. Catheter Cardiovasc Interv 2010, 76(6):865-873.
34. Nagaya N., Nishikimi T., Okano Y., et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998, 31(1):202-208.
35. Mauritz G.J., Rizopoulos D., Groepenhoff H., et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 2011, 108(11):1645-1650.
36. Vijlbrief D.C., Benders M.J., Kemperman H., van Bel F., de Vries W.B. B-type natriuretic peptide and rebound during treatment for persistent pulmonary hypertension. J Pediatr 2012, 160(1):111-115.
37. Vijlbrief D.C., Benders M.J., Kemperman H., van Bel F., de Vries W.B. Use of cardiac biomarkers in neonatology. Pediatr Res 2012, 72(4):337-343.
38. Reynolds E.W., Ellington J.G., Vranicar M., Bada H.S. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004, 114(5):1297-1304.
39. Nir A., Lindinger A., Rauh M., et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009, 30(1):3-8.
40. Kim G.B. Pulmonary hypertension in infants with bronchopulmonary dysplasia. Korean J Pediatr 2010, 53(6):688-693.
41. Warwick G., Thomas P.S., Yates D.H. Biomarkers in pulmonary hypertension. Eur Respir J 2008, 32(2):503-512.
42. Warner B.B., Stuart L.A., Papes R.A., Wispe J.R. Functional and pathological effects of prolonged hyperoxia in neonatal mice. Am J Physiol 1998, 275(1 Pt 1):L110-L117.
43. Lakshminrusimha S., Swartz D.D., Gugino S.F., et al. Oxygen concentration and pulmonary hemodynamics in newborn lambs with pulmonary hypertension. Pediatr Res 2009, 66(5):539-544.
44. Lakshminrusimha S., Steinhorn R.H., Wedgwood S., et al. Pulmonary hemodynamics and vascular reactivity in asphyxiated term lambs resuscitated with 21 and 100% oxygen. J Appl Physiol 2011, 111(5):1441-1447.
45. Ivy D.D., Parker D., Doran A., Kinsella J.P., Abman S.H. Acute hemodynamic effects and home therapy using a novel pulsed nasal nitric oxide delivery system in children and young adults with pulmonary hypertension. Am J Cardiol 2003, 92(7):886-890.
46. Rubin L.J., Badesch D.B., Fleming T.R., et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: SUPER-2. Chest 2011, 140(5):1274-1283.
47. Baquero H., Soliz A., Neira F., Venegas M.E., Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006, 117(4):1077-1083.
48. Barst R.J., Ivy D.D., Gaitan G., et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 2012, 125(2):324-334.
49. U.S. Food and Drug Administration. FDA drug safety communication: FDA recommends against use of revatio in children with pulmonary hypertension. 2012 [updated 30.08.12]. http://www.fda.gov/Drugs/DrugSafety.
50. Abman S.H, Kinsella J.P, Rosenzweig E.B, et al. Implications of the FDA warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med 2013 [in press], PMID: 23220921.
51. Mourani P.M., Sontag M.K., Ivy D.D., Abman S.H. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009, 154(3):379-384. [384.e1-2].
52. Farrow K.N., Steinhorn R.H. Sildenafil therapy for bronchopulmonary dysplasia: not quite yet. J Perinatol 2012, 32(1):1-3.
53. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992, 327(2):70-75.
54. Lakshminrusimha S., Porta N.F., Farrow K.N., et al. Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 2009, 10(1):106-112.
55. Rosenzweig E.B., Kerstein D., Barst R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999, 99(14):1858-1865.
56. Barst R.J., Maislin G., Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999, 99(9):1197-1208.
57. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996, 334(5):296-302.
58. Barst R.J., Rubin L.J., McGoon M.D., Caldwell E.J., Long W.A., Levy P.S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994, 121(6):409-415.
59. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002, 40(4):780-788.
60. Yung D., Widlitz A.C., Rosenzweig E.B., Kerstein D., Maislin G., Barst R.J. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004, 110(6):660-665.
61. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115(5):343-349.
62. Zaidi A.N., Dettorre M.D., Ceneviva G.D., Thomas N.J. Epoprostenol and home mechanical ventilation for pulmonary hypertension associated with chronic lung disease. Pediatr Pulmonol 2005, 40(3):265-269.
63. Doran A.K., Ivy D.D., Barst R.J., Hill N., Murali S., Benza R.L. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008, 160:5-9.
64. Ewert R., Schaper C., Halank M., Glaser S., Opitz C.F. Inhalative iloprost-pharmacology and clinical application. Expert Opin Pharmacother 2009, 10(13):2195-2207.
65. Ivy D.D., Doran A.K., Smith K.J., et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008, 51(2):161-169.
66. Ivy D.D., Claussen L., Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. Am J Cardiol 2007, 99(5):696-698.
67. Levy M., Celermajer D.S., Bourges-Petit E., Del Cerro M.J., Bajolle F., Bonnet D. Add-on therapy with subcutaneous treprostinil for refractory pediatric pulmonary hypertension. J Pediatr 2011, 158(4):584-588.
68. Krishnan U., Takatsuki S., Ivy D.D., et al. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. Am J Cardiol 2012, 110(11):1704-1709.
69. Abman S.H. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Annu Rev Med 2009, 60:13-23.
70. Giaid A., Yanagisawa M., Lagleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:1732-1739.
71. Beghetti M. Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. Eur J Clin Invest 2006, 36(suppl 3):16-24.
72. Maiya S., Hislop A.A., Flynn Y., Haworth S.G. Response to bosentan in children with pulmonary hypertension. Heart 2006, 92(5):664-670.
73. Rugolotto S., Errico G., Beghini R., Ilic S., Richelli C., Padovani E.M. Weaning of epoprostenol in a small infant receiving concomitant bosentan for severe pulmonary arterial hypertension secondary to bronchopulmonary dysplasia. Minerva Pediatr 2006, 58(5):491-494.
74. Beghetti M., Hoeper M.M., Kiely D.G., et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European postmarketing surveillance program. Pediatr Res 2008, 64(2):200-204.
75. O'Reilly M., Thebaud B. Cell-based strategies to reconstitute lung function in infants with severe bronchopulmonary dysplasia. Clin Perinatol 2012, 39(3):703-725.
76. van Haaften T., Byrne R., Bonnet S., et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 2009, 180(11):1131-1142.
77. Aslam M., Baveja R., Liang O.D., et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med 2009, 180(11):1122-1130.
78. Hansmann G., Fernandez-Gonzalez A., Aslam M., et al. Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulm Circ 2012, 2(2):170-181.